In an effort to improve compliance, decrease adverse effects, minimize drug interactions, and help with costs I am trying to update my institutions preferred PEP regimen.
the guidelines are outdated as there have been many advancements in ART since then and they really only cite evidence in HIV treatment and side effects as how to choose a preferred regimen anyway.
I want to use BIC/F/TAF. But most of our PEP patients are female sexual assault survivors. And the data thus far are primarily in MSM. Even that is a small number.
Is anyone using BIC/F/TAF at your institution? Or another STR?
------------------------------
Katy Garrett, PharmD, BCIDP, AAHIVP
HIV/HCV/HBV Clinical Pharmacist
Portland ME
------------------------------